Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Laura is the vice president of content for 

) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

Controversy surrounds the Advisory Committee on Immunization Practices’ (ACIP) first meeting under new leadership as vaccine skeptics join the panel.

CDC Vaccine Panel Meets for First Time After RFK Jr Expelled Former Members

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Videos

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.

Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD

Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the Italian-based GIMEMA Foundation.

Quality of Life Disparities Persist in R/R Multiple Myeloma Despite Universal Health Care: Francesco Sparano, MSc

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

Gastroenterology

ALL/AML

CLL/SLL

GVHD

Hemophilia

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Rare Blood

Hematology

Liver

MASH

Hepatology

Allergy

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Rheumatoid Arthritis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Obesity

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Small Cell Lung Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Pulmonary Fibrosis

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Participating Faculty

Introduction

Modeling of Medical and Surgical Treatment Costs of Chronic Pelvic Pain:  new Paradigms for Making Clinical Decisions

Primary Gonadotropin-Releasing Hormone Agonist Therapy for Suspected Endometriosis:  A Nonsurgical Approach to the Diagnosis and Treatment of Chronic Pelvic Pain

The Cost of Inpatient Endometriosis Treatment:  An Analysis Based on the Healthcare Cost and Utilization Project Nationwide Inpatient Sample

The Clinical and Economic Benefits of GnRH Agonist in Treating Endometriosis

Newsletter